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Abstract
Background: Uropathogenic Escherichia coli O- Serogroups with their virulence factors are the most prevalent
causes of UTIs. The present research performed to track common uropathogenic E.coli serogroups, antibiotic
resistance pattern of strains and prevalence of virulence genes in isolations having the ability to constitute
biofilm.
Methods: In this research 130 E.coli isolation from patients having UTI symptoms were collected and
antimicrobial resistance pattern was performed by Kirby-Bauer method. Polymerase chain reaction was done
using primer pairs to identify common serogroups of uropathogenic E.coli and studying virulence genes in
isolations creating biofilm.
Results: Among 130 E.coli isolates, 80 (61.53 %) were able to make biofilm that 15 isolates (18.75 %) indicated
strong reaction, 20 (25 %) of medium and 45 (56.25 %) of weak biofilm reaction. Among isolations creating
biofilm, the highest resistance reported to Ampicillin (87.5 %) and the lowest to Nitrofurantoin (3.75 %). The
frequency of fimH, pap, sfa and afa genes in isolations having the ability to create strong biofilm reported
93.33 %, 86.66 %, 86.66 % and 66.66 %, respectively.
Conclusions: The findings indicated the importance of virulence genes in serogroups producing
uropathogenic E.coli biofilm. It is recommended that strains producing biofilm before antibiotic use should be
studied.
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Background
Urinary tract infections (UTI) are common causes of
morbidity and sometimes lead to significant mortality.
Escherichia coli (E. coli) was the most common etio-
logical agent of UTI, accounting for nearly 80 % of
community-acquired and 50 % of hospital-acquired in-
fections [1] and tends to form microcolonies in mucosa
lining of urinary bladder known as biofilm. These
biofilms make the organism to resist the host immune
response, more virulent and lead to the evolution of
antibacterial drug resistance by enclosing them in an
extracellular biochemical matrix [2]. Biofilms have a role
in up to 60 % of human infections and they are very
difficult to be eradicated with antimicrobial therapy. In
vitro susceptibility tests have shown considerable increase
in resistance of biofilm cells to killing [3]. Detection of
biofilm-producer strains is therefore relevant for the
design of adequate control measures for Uropatho-
genic E. coli (UPEC) infections.
The Escherichia coli strains are normally identified by
serological typing of their H (flagellar), O (lipopolysac-
charide) and in some cases, K (capsular) surface antigens.
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Overall, 184 O-serogroups are described for E. coli [4].
The O-serogroups of UPEC strains are related to certain
virulence factor profile of each strain. Previous studies re-
ported that O1, O2, O4, O6, O7, O8, O15, O16, O18,
O21, O22, O25, O75 and O83 serogroups are preferen-
tially associated with UPEC strains [5–13]. Some of the
most important virulence genes of UPEC strains which
are associated with severe UTIs are P fimbriae (pap), type
1 fimbriae, afimbrial adhesin I (afaI), hemolysin (hly),
cytotoxic necrotizing factor 1 (cnf 1), aerobactin (aer), S
fimbriae (sfa), adhesins and fimbriae [14, 15]; however,
other virulence genes such as kpsMT, ompT, usp, iroN,
iha, set 1, astA, group II capsule synthesis; sfa/foc, S and
F1C fimbriae; iutA, traT, serum resistance; and fimH, are
known to be involved in pathogenicity of this organism
[16–18]. These Virulence factors help the organisms to
colonize host surfaces, avoid and/or subvert host defense
mechanisms, injure and/or invade host cells and tissues,
and incite a noxious inflammatory response, thereby lead-
ing to clinical disease [19]. Uropathogenic E. coli strains
more frequently produce Pap and Prs fimbrial adhesins. P
fimbriae are important for colonization and persistence of
E. coli in the colon and possibly facilitate spread to the
urinary tract [20, 21]. The ability to constitute biofilm
plays an important role in virulence of the bacteria, in
addition to it; various genes encode urinary virulence
factors.
In addition, several studies showed that antibiotic re-
sistance in UPEC is increasing nowadays [22, 23]. Sev-
eral studies have reported increasing trends in resistance
against trimethoprim-sulfamethoxazole (TMP -SMZ)
[24, 25] fluoroquinolones and other antibiotics, includ-
ing ciprofloxacin [26, 27]. To reduce the rate of morbid-
ity, an early treatment of UTIs is mandatory, which
relays on empirical therapies. However, to initiate an ef-
fective empirical treatment, several factors must be taken
into consideration, including geographical location, age
and sex of the patient, and local antimicrobial resistance
profiles of the pathogens.
The identification of bacterial resistance genes seems
to be essential to reduce the treatment costs. Using
phylogenetic grouping as defined by multilocus enzyme
electrophoresis and muliplex polymerase chain reaction
(PCR) assays, Johnson et al. reported detailed analyses
about phylogenetic background and virulence attributes
of uropathogenic E. coli strains isolated from urosepsis
and cystitis [28]. To our knowledge, there is scarcity of
data showing the common uropathogenic E. coli ser-
ogroups in causing urinary tract infections, antibiotic re-
sistance pattern of strains and frequency distribution of
types of virulence genes in isolations having the ability
to constitute biofilm in Iran. Therefore, in this study, we
determined to track the common uropathogenic E. coli
serogroups, antimicrobial susceptibility patterns and the
virulence gene distribution of UPEC strains having the
ability to constitute biofilm isolated from patients with
UTIs in Iran.
Methods
Bacterial strains and detection of uropathogenic E. coli
serogroups and virulence genes
In the present study, a total of 130 E. coli strains isolates
were isolated and collected from urine specimens of pa-
tients with UTI who that had been referred to the med-
ical laboratory. The strains were isolated from pure
cultures and identified and also confirmed biochemically
and using molecular techniques in the laboratory.
The colonies were confirmed using Polymerase Chain
Reaction (PCR) based on the detection of 16S rRNA
gene region of E. coli described by Sabat et al., (2000)
[29]. In addition, all isolates were serogrouped using
PCR assays. Table 1 showed the primers used for detec-
tion of UPEC serogroups and the PCR conditions [30].
The oligonucleotide sequences and Multiplex Polymer-
ase Chain Reaction conditions of the specific primers
were used to amplify the pap, fimH, sfa and afa genes
producing biofilm in uropathogenic E. coli are shown in
Table 2 [30]. The amplified products were visualized by
ethidium bromide staining after gel electrophoresis of
10 μL of the final reaction mixture in 1.5 % agarose.
Detection of biofilm formation and antimicrobial
susceptibility testing
All E. coli strains were included in the study and were
analyzed for the production of biofilm and antimicrobial
susceptibility pattern. Biofilm production in bacterial
cultures was determined by Congo-red Agar method
(CRA) as described previously by Solati et al. [31].
Congo-red was prepared as the aqueous solution, auto-
claved, and then added when the agar cooled to 55 °C.
Plates were inoculated and incubated for 24 hours at
37 °C. The positive isolate was indicated by black and
dry crystalline colonies. Weak biofilm producers usually
remained pink with the darkness at the center of col-
onies. Intermediate results were exhibited by the dark-
ness of the colonies with the absence of a dry crystalline
colonies.
Antimicrobial susceptibility testing was done by the
Kirby–Bauer disc diffusion method using Mueller–Hinton
agar (HiMedia Laboratories, Mumbai, India) according to
the Clinical Laboratory Standards Institute (CLSI) guide-
lines [32] as has been previously described [30].
The antimicrobial agents tested and their corresponding
concentrations were ampicillin (AM), tetracycline (TE),
nalidixic acid (NA), co-trimoxazole (SXT), cephalothin
(CF), ciprofloxacin (CP), norfloxacin (NOR), ceftriaxone
(CRO), amikacin (AN), imipenem (IMP), gentamicin
(GM) and nitrofurantoin (FM).
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Table 1 The oligonucleotide primers and the Multiplex PCR programs used for amplification of O-serogroups genes of E. coli
isolates
Serotypes Gene Primer name Primer Sequence (5'-3) Size of
product (bp)
PCR programs M-PCR Volume (50 μL)
O1 Wzx wl-14632 GTGAGCAAAAGTGAAATAAGGAACG 1098 1 cycle:
95 °C ------------ 5 min.
30 cycle:
95 °C ------------ 30 s
62 °C ------------ 60 s
72 °C ------------ 60 s
1 cycle:
72 °C ------------ 5 min
5 μL PCR buffer 10X
2.5 mM Mgcl2
300 μM dNTP (Fermentas)
0.4 μM of each primers F & R
2 U Taq DNA polymerase (Fermentas)
3 μL DNA template
wl-14633 CGCTGATACGAATACCATCCTAC
O6 Wzy wl-14646 GGATGACGATGTGATTTTGGCTAAC 783
wl-14647 TCTGGGTTTGCTGTGTATGAGGC
O7 Wzx wl-14648 CTATCAAAATACCTCTGCTGGAATC 610
wl-14649 TGGCTTCGAGATTAAACCTATTCCT
O8 orf469 wl-14652 CCAGAGGCATAATCAGAAATAACAG 448
wl-14653 GCAGAGTTAGTCAACAAAAGGTCAG
O16 Wzx wl-14654 GGTTTCAATCTCACAGCAACTCAG 302
wl-14655 GTTAGAGGGATAATAGCCAAGCGG
O21 Wzx wl-14676 CTGCTGATGTCGCTATTATTGCTG 209
wl-14677 TGAAAAAAAGGGAAACAGAAGAGCC
O75 Wzy wl-17413 GAGATATACATGGGGAGGTAGGCT 511
wl-17414 ACCCGATAATCATATTCTTCCCAAC
O2 Wzy wl-14636 AGTGAGTTACTTTTTAGCGATGGAC 770 1 cycle:
95 °C ------------ 5 min.
30 cycle:
94 °C ------------ 60 s
58 °C ------------ 60 s
5 μL PCR buffer 10X
2.5 mM Mgcl2
300 μM dNTP (Fermentas)
0.4 μM of each primers F & R
2 U Taq DNA polymerase (Fermentas)
wl-14637 AGTTTAGTATGCCCCTGACTTTGAA
O4 Wzx wl-14642 TTGTTGCGATAATGTGCATGTTCC 664
wl-14643 AATAATTTGCTATACCCACACCCTC
O15 Wzy wl-14672 TCTTGTTAGAGTCATTGGTGTATCG 183
wl-14673 ATAAAACGAGCAAGCACCACACC
O18 Wzx wl-14656 GTTCGGTGGTTGGATTACAGTTAG 551
wl-14657 CTACTATCATCCTCACTGACCACG
O22 Wzx wl-14660 TTCATTGTCGCCACTACTTTCCG 468
wl-14661 GAAACAGCCCATGACATTACTACG
O25 Wzy wl-14666 AGAGATCCGTCTTTTATTTGTTCGC 230
wl-14667 GTTCTGGATACCTAACGCAATACCC
O83 Wzx wl-14668 GTACACCAGGCAAACCTCGAAAG 362
wl-14669 TTCTGTAAGCTAATGAATAGGCACC
Table 2 The oligonucleotide primers and the Multiplex PCR programs used for amplification of virulence genes of E. coli isolates






94 °C ------------ 1 min.
30 cycle:
94 °C ------------ 60 s
63 °C ------------ 30 s
72 °C ------------ 90 s
1 cycle:
72 °C ------------ 5 min
5 μL PCR buffer 10X
1.25 mM Mgcl2
150 μM dNTP (Fermentas)
1 μM of each primers F & R
1.2 U Taq DNA polymerase (Fermentas)

















94 °C ------------ 3 min.
40 cycle:
94 °C ------------ 60 s
58 °C ------------ 70 s
72 °C ------------ 70 s
1 cycle:
72 °C ------------ 6 min
5 μL PCR buffer 10X
2 mM Mgcl2
200 μM dNTP (Fermentas)
0.4 μM of each primers F & R
1 U Taq DNA polymerase (Fermentas)
3 μL DNA template
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Statistical analysis
SPSS version 17.0 statistical software package was used
for statistical analysis. Chi-square test was applied.
P-value < 0.05 was considered statistically significant
Results
Among 130 E.coli isolates, 80 (61.53 %) were able to make
biofilm. Among 80 E. coli strains subjected to biofilm pro-
duction, 15 (18.75 %) strains showed highly positive with
very black colonies color in Congo Red Agar (CRA), 20
strains (25 %) showed moderate positive with black col-
onies color in CRA, 45 strains (56.25 %) showed weakly
positive with grey colonies color in CRA. Dry crystalline
and black colonies at the Congo-red Agar culture, were
considered as strong biofilm producers; isolates did not
show dry crystalline black colonies were identified as
moderately biofilm producers and non-biofilm producers
showed pink or yellow colonies.
Antibiotic susceptibility pattern was studied for all
E. coli isolates. The multi-drug resistant pattern of
the biofilm producing and non producing UPEC E.
coli is shown in Table 3. All the biofilm forming
strains showed maximum resistance to ampicillin
(87.5 %), followed by tetracycline (75 %), nalidixic
Acid (72.5 %) and co-trimoxazole (71.25 %). Both bio-
film producer and non- biofilm producer were highly
resistant to ampicillin, followed by tetracycline and
nalidixic acid. 93.75 % and 98 % sensitive was noticed
for biofilm and non-biofilm producer against nitrofur-
antoin, respectively.
Our results revealed high distribution of UPEC ser-
ogroups isolated from patients with urinary tract infec-
tion. Totally, O25 (26.66 %), O15 (20.0 %) and O16
(13.33 %) had the highest biofilm producing serogroups
while O2, O4, O6, O8, O21 and O22 had the lowest
biofilm producing serogroups which showed (6.66 %)
among Uropathogenic E. coli isolates detected (Table 4).
In the present study the prevalence of fimH, pap, sfa
and afa genes in Uropathogenic E. coli was determined
and the result showed that among high biofilm producer
Uropathogenic E. coli isolates fimH gene was the highest
prevalence and afa gene was the lowest prevalence viru-
lence gene (Table 5). Biofilm production was signifi-
cantly associated with fimH, pap, afa and sfa virulence
genes (P < 0.05).
Discussion
Urinary tract infections are among the most common
bacterial diseases worldwide which involve (infects) about
250 million people in developing countries annually [33,
34]. Uropathogenic E. coli alone account for 70-90 % of
the UTI infections [35, 36] and their susceptibility pat-
terns against different antibiotics vary in different geo-
graphical regions, eventually leading to empirical therapy
which is based on the local susceptibility profiles. Bacterial
biofilm are often associated with long-term persistence of
organism in various environments. Bacteria in biofilm dis-
play dramatically increased resistance to antibiotics [37].
Among 80 E. coli isolates subjected to biofilm production,
15 (18.75 %) isolates showed highly positive, 20 isolates
(25 %) showed moderate positive, 45 isolates (56.25 %)
showed weakly positive in Congo Red Agar method (CRA).
Antibiotic susceptibility pattern was studied for all E. coli
isolates.
The biofilm forming isolates showed maximum resist-
ance to Ampicillin (87.5 %), followed by Tetracycline
(75 %), Nalidixic Acid (72.5 %) and Co-Trimoxazole
(71.25 %). Both biofilm producer and non- biofilm pro-
ducer were highly resistant to Ampicillin, followed by
Tetracycline and Nalidixic Acid. 93.75 % and 98 %
Table 3 Antibiotic resistance pattern of the biofilm producing and non producing Uropathogenic E. coli
Antibiotic Biofilm producer (N = 80) Non biofilm producer (N = 50)
Resistance Sensitive Resistance Sensitive
Ampicillin (AM) 70 (87.5 %) 10 (12.5 %) 40 (80 %) 10 (20 %)
Tetracycline (TE) 60 (75 %) 20 (25 %) 35 (70 %) 15 (30 %)
Nalidixic Acid (NA) 58 (72.5 %) 22 (27.5 %) 34 (68 %) 16 (32 %)
Co-Trimoxazole (SXT) 57 (71.25 %) 23 (28.75 %) 33 (66 %) 17 (34 %)
Cephalothin (CF) 45 (56.25 %) 35 (43.75 %) 28 (56 %) 22 (44 %)
Ciprofloxacin (CP) 45 (56.25 %) 35 (43.75 %) 27 (54 %) 23 (46 %)
Norfloxacin (NOR) 43 (53.75 %) 37 (46.25 %) 26 (52 %) 24 (48 %)
Ceftriaxone (CRO) 33 (41.25 %) 47 (58.75 %) 20 (40 %) 30 (60 %)
Amikacin (AN) 31 (38.75 %) 49 (61.25 %) 18 (36 %) 32 (64 %)
Imipenem (IMP) 25 (31.25 %) 55 (68.75 %) 15 (30 %) 35 (70 %)
Gentamicin (GM) 15 (18.75 %) 65 (81.25 %) 9 (18 %) 41 (82 %)
Nitrofurantoin (FM) 5 (6.25 %) 75 (93.75 %) 1 (2 %) 49 (98 %)
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Table 4 Prevalence of serogroups Uropathogenic E. coli
Number of positive
samples
Prevalence of serogroups (%)
O1 O2 O4 O6 O7 O8 O15 O16 O18 O21 O22 O25 O75 O83
High Biofilm Production
E. coli (N = 15)
- 1 (6.66 %) 1 (6.66 %) 1 (6.66 %) - 1 (6.66 %) 3 (20 %) 2 (13.33 %) - 1 (6.66 %) 1 (6.66 %) 4 (26.66 %) - -
Moderate Biofilm
Production E. coli (N = 20)
1 (5 %) 1 (5 %) 1 (5 %) 1 (5 %) 1 (5 %) 1 (5 %) 3 (15 %) 2 (10 %) 1 (5 %) 1 (5 %) 1 (5 %) 5 (25 %) 1 -
Weak Biofilm Production
E. coli (N = 45)
1 (2.22 %) 1 (2.22 %) 2 (4.44 %) 6 (13.33 %) 1 (2.22 %) 1 (2.22 %) 10 (22.22 %) 5 (11.11 %) 1 (2.22 %) 2 (4.44 %) 1 (2.2 %) 13 (28.88 %) 1 (2.22 %) -













sensitivity was noticed for biofilm and non-biofilm produ-
cer against Nitrofurantoin, respectively. The findings of the
current investigations are in agreement with the reports of
Reisner et al. [38] ; Ong et al. [39]; Ulett et al. [40] and Ulett
et al. [41] in which a greater variation was observed against
the uropathogenic E. coli forming biofilms under different
conditions. Another finding of this study is that strong bio-
film producers were less susceptible to antimicrobial agents
than the non-biofilm producer. This result may agree with
the previous studies showing that the sessile bacterial cells
seems to exhibit higher resistance than the planktonic cells
[42–48], so the findings of the current investigation indi-
cated that resistance mechanisms are associated with the
formation of biofilm among uropathogenic E. coli.
Similarly, the increasing prevalence of multi-drug re-
sistance (MDR) has been reported by other workers
showed, of the 100 (60.2 %) E. coli strains, 72 strains dis-
played a biofilm positive phenotype under the optimized
conditions in the Congo Red agar medium and the
strains were classified as highly positive (17, 23.6 %),
moderate positive (19, 26.3 %) and weakly positive (36,
50.0 %). The rates of antibiotic resistance of biofilm pro-
ducing E. coli were found to be 100 % for chlorampheni-
col and amoxyclav (amoxicillin and clavulanic acid),
86 % for gentamicin and cefotaxime, 84 % for ceftazi-
dime, 83 % for cotrimoxazole and piperacillin/tazobac-
tam, 75 % for tetracycline and 70 % for amikacin [49].
This could be due to dissemination of MDR strains in
hospital settings and the different combination of antibi-
otics resulted in varying degree of resistance among the
biofilm producing uropathogenic E. coli.
In addition, 56.25 % of biofilm-producing UPEC iso-
lates showed resistance to Cephalothin. Similar findings
had been previously observed in South East Asian region
[50–52]. Reported resistance rate against these drugs was
comparatively lower in previous study in Iran (19.6 %)
[53] and in Bangladesh, it was 32 % [54]. However, ob-
served higher percentages of resistances against Cephalo-
thin drugs indicated that they could render their efficacies
as therapeutic agents, particularly in Iranian population.
In general, our results suggest that transformation of UTI-
associated E. coli with plasmids carrying different anti-
biotic resistance gene had a significant impact on biofilm
formation and that these effects were both strain dependent
and varied between different antibiotics.
Our results revealed high distribution of UPEC ser-
ogroups isolated from patients with urinary tract infec-
tion. Totally, O25 (26.66 %), O15 (20.0 %) and O16
(13.33 %) had the highest biofilm producing serogroups
while O2, O4, O6, O8, O21 and O22 had the lowest
biofilm producing serogroups which showed (6.66 %)
among Uropathogenic E. coli isolates detected
(Table 4). In the present study the prevalence of fimH,
pap, sfa and afa genes in Uropathogenic E. coli was
determined and the result showed that among High
biofilm producer Uropathogenic E. coli isolates fimH
gene was the highest prevalence and afa gene was the
lowest prevalence virulence gene (Table 5). Biofilm
production was significantly associated with fimH, pap,
afa and sfa virulence genes (P < 0.05). Manuela et al.
reported that Biofilm production was significantly as-
sociated with fluoroquinolone resistance at all incuba-
tion time points and was independent of the media
used (P < 0.05). Biofilm production was not associated
with cnf1, hly, pap and sfa genes (P > 0.05), but was sig-
nificantly associated with afa, aer and the β-lactamase
genes (P < 0.05) [55].
Conclusions
Urinary tract infections are one of the common infec-
tions which are encountered in the clinical practice.
This study reveals the prevalence and antimicrobial sus-
ceptibility pattern of biofilm and non-biofilm producing
uropathogenic E. coli strains. Biofilm formation is
closely related with the resistance of E. coli towards the
antimicrobial drugs and also it increases the chronicity
of urinary tract infection. In general, the current study
demonstrated a high tendency among the clinical iso-
lates of E. coli to form biofilm. The present study has
also shown the production of various virulent factors
and developing drug resistance in UPEC. Antibiotic re-
sistance may provide a substantial advantage to the sur-
vival of the pathogen. The drug resistance among UPEC
is on rise therefore the selection of appropriate antibi-
otics (after antibiotic susceptibility testing) is must for
proper treatment of patients and to avoid emergence of
drug resistance. Therefore, the knowledge of virulence
factors of E. coli and their antibiotic susceptibility pattern
will help in better understanding of the organism and in
the treatment of UTI.




High biofilm producer 15 Moderate biofilm producer 20 Weak biofilm producer 45 Non biofilm producer 50 P value
fimH 14 (93.33 %) 18 (90 %) 35 (77.77 %) 30 (60 %) 0.031
pap 13 (86.66 %) 16 (80 %) 30 (71.42 %) 28 (56 %) 0.001
sfa 13 (86.66 %) 10 (50 %) 20 (44.44 %) 20 (40 %) 0.033
afa 10 (66.66 %) 7 (35 %) 15 (33.33 %) 10 (20 %) 0.035
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